IQV
IQVIA Holdings Inc. NYSE$160.94
Mkt Cap $27.3B
52w Low $134.65
23.4% of range
52w High $247.05
50d MA $168.99
200d MA $196.97
P/E (TTM)
19.9x
EV/EBITDA
15.3x
P/B
4.1x
Debt/Equity
2.5x
ROE
20.9%
P/FCF
18.9x
RSI (14)
—
ATR (14)
—
Beta
1.39
50d MA
$168.99
200d MA
$196.97
Avg Volume
2.1M
About
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 5, 2026 | BMO | 3.40 | 3.42 | +0.6% | 180.96 | +1.2% | +3.6% | +3.6% | +6.5% | +0.8% | -2.1% | — |
| Oct 28, 2025 | BMO | 2.98 | 3.00 | +0.7% | 218.13 | +0.9% | -0.1% | -0.1% | -0.8% | -0.8% | -1.9% | — |
| Jul 22, 2025 | BMO | 2.77 | 2.81 | +1.4% | 187.38 | +2.1% | +3.7% | +3.7% | +7.2% | +6.3% | +5.5% | — |
| May 6, 2025 | BMO | 2.63 | 2.70 | +2.7% | 146.20 | +2.3% | +4.9% | +4.9% | +4.8% | +1.9% | +6.8% | — |
| Feb 6, 2025 | BMO | 3.11 | 3.12 | +0.3% | 209.96 | +0.8% | -0.9% | -0.9% | -1.4% | -4.3% | -5.8% | — |
| Oct 31, 2024 | BMO | 2.82 | 2.84 | +0.7% | 205.82 | +0.1% | +1.6% | +1.6% | +2.1% | +3.4% | +7.5% | — |
| Jul 22, 2024 | BMO | 2.56 | 2.64 | +3.1% | 245.23 | -1.3% | -2.6% | -2.6% | -2.6% | -5.3% | -2.3% | — |
| May 2, 2024 | BMO | 2.49 | 2.54 | +2.0% | 222.14 | +0.6% | +0.6% | +0.6% | +2.2% | +3.2% | +2.6% | — |
| Feb 14, 2024 | BMO | 2.82 | 2.84 | +0.7% | 243.47 | -0.6% | -0.8% | -0.8% | -2.0% | -3.6% | -2.5% | — |
| Nov 1, 2023 | BMO | 2.46 | 2.49 | +1.2% | 180.01 | +0.6% | +5.8% | +5.8% | +9.5% | +10.2% | +11.1% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 8 | Evercore ISI | Maintains | Outperform → Outperform | — | $170.62 | $175.39 | +2.8% | +1.1% | -1.0% | -1.9% | +0.8% | +2.7% |
| Mar 9 | TD Cowen | Upgrade | Hold → Buy | — | $174.49 | $174.49 | +0.0% | +2.3% | -2.0% | -1.7% | -6.6% | -5.6% |
| Mar 6 | Barclays | Upgrade | Equal Weight → Overweight | — | $178.50 | $178.20 | -0.2% | -2.2% | +0.0% | -4.2% | -3.9% | -8.7% |
| Feb 19 | Truist | Maintains | Buy → Buy | — | $171.06 | $169.05 | -1.2% | -1.0% | -3.2% | -5.1% | -3.6% | -5.3% |
| Feb 6 | Stifel | Maintains | Buy → Buy | — | $180.96 | $183.12 | +1.2% | +3.6% | +6.5% | +0.8% | -2.1% | -6.7% |
| Feb 6 | Citigroup | Maintains | Neutral → Neutral | — | $180.96 | $183.12 | +1.2% | +3.6% | +6.5% | +0.8% | -2.1% | -6.7% |
| Feb 6 | JP Morgan | Maintains | Overweight → Overweight | — | $180.96 | $183.12 | +1.2% | +3.6% | +6.5% | +0.8% | -2.1% | -6.7% |
| Feb 6 | Jefferies | Maintains | Buy → Buy | — | $180.96 | $183.12 | +1.2% | +3.6% | +6.5% | +0.8% | -2.1% | -6.7% |
| Feb 6 | Barclays | Maintains | Equal Weight → Equal Weight | — | $180.96 | $183.12 | +1.2% | +3.6% | +6.5% | +0.8% | -2.1% | -6.7% |
| Feb 6 | UBS | Maintains | Buy → Buy | — | $180.96 | $183.12 | +1.2% | +3.6% | +6.5% | +0.8% | -2.1% | -6.7% |
Recent Filings
8-K · 2.02
!! High
IQVIA Holdings Inc. -- 8-K 2.02: Earnings Results
IQVIA Holdings reported Q1 2026 earnings results on May 5, demonstrating operational performance across its clinical research, software, and technology services segments.
May 5
8-K
IQVIA Holdings Inc. -- 8-K Filing
IQVIA's executive compensation plan allows the Compensation Committee to establish performance metrics and award share payouts within predetermined ranges based on achievement of corporate goals.
Apr 23
8-K · 7.01
! Medium
Charles River Laboratories International, Inc. -- 8-K 7.01: Regulation FD Disclosure
Charles River Laboratories plans to divest its CDMO and Cell Solutions businesses, eliminating revenue streams from advanced therapy manufacturing services and cellular materials, potentially impacting investor returns.
Feb 25
8-K · 5.02
!!! Very High
Baxter International Inc. -- 8-K 5.02: Executive Change
Baxter International appointed Michael R. McDonnell as Executive Vice President effective February 13, 2026, signaling internal leadership development and potential changes to executive responsibilities.
Feb 12
8-K
IQVIA Holdings Inc. -- 8-K Filing
IQVIA delivered strong fourth-quarter 2025 results across all business segments, demonstrating solid operational momentum for the healthcare intelligence and clinical research provider.
Feb 5
Data updated apr 25, 2026 4:10pm
· Source: massive.com